Onconetix prices USD 30.25 million PIPE via Series F convertible preferred stock sale

Registration rights were granted for the common shares issuable on conversion.

Onconetix entered a $30.25 million PIPE on July 28, 2026 through an unregistered sale of 37,812 shares of Series F convertible preferred stock.

• Series F carries a $1,000 stated value per share.
• The preferred stock is convertible into common stock at an initial conversion price of $0.98.